HCA Healthcare (NYSE:HCA – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported $5.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.97 by $0.53, Briefing.com reports. The company had revenue of $17.49 billion for the quarter, compared to the consensus estimate of $17.05 billion. HCA Healthcare had a return on equity of 621.57% and a net margin of 8.40%. HCA Healthcare’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $4.29 earnings per share. HCA Healthcare updated its FY 2024 guidance to 21.600-22.800 EPS.
HCA Healthcare Stock Up 1.1 %
NYSE:HCA opened at $343.94 on Thursday. The stock’s fifty day moving average is $328.88 and its two-hundred day moving average is $322.41. HCA Healthcare has a 52 week low of $215.96 and a 52 week high of $348.00. The company has a quick ratio of 1.02, a current ratio of 1.16 and a debt-to-equity ratio of 29.26. The stock has a market capitalization of $90.08 billion, a price-to-earnings ratio of 17.15, a price-to-earnings-growth ratio of 1.45 and a beta of 1.68.
HCA Healthcare Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 16th will be given a dividend of $0.66 per share. The ex-dividend date of this dividend is Monday, September 16th. This represents a $2.64 dividend on an annualized basis and a dividend yield of 0.77%. HCA Healthcare’s payout ratio is currently 13.16%.
Insider Buying and Selling
Analyst Ratings Changes
Several equities analysts have issued reports on HCA shares. TD Cowen decreased their price objective on shares of HCA Healthcare from $371.00 to $360.00 and set a “buy” rating on the stock in a report on Tuesday, April 30th. Royal Bank of Canada increased their target price on HCA Healthcare from $329.00 to $378.00 and gave the company an “outperform” rating in a report on Wednesday. JPMorgan Chase & Co. increased their price objective on HCA Healthcare from $327.00 to $332.00 and gave the company a “neutral” rating in a research note on Thursday, May 30th. Wells Fargo & Company upped their target price on shares of HCA Healthcare from $303.00 to $315.00 and gave the stock an “equal weight” rating in a report on Thursday, March 28th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $335.00 price objective on shares of HCA Healthcare in a research note on Wednesday. Four investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, HCA Healthcare presently has a consensus rating of “Moderate Buy” and a consensus target price of $339.72.
Get Our Latest Stock Analysis on HCA Healthcare
About HCA Healthcare
HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.
Recommended Stories
- Five stocks we like better than HCA Healthcare
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- How Much Should You Be Investing? Try Our Calculators
- What Are Growth Stocks and Investing in Them
- Enphase Energy Stock: Growth in the Renewable Energy Transition
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- ASML Stock Nearing Bottom: Is Now the Time to Buy?
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.